Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001437

Nateglinide

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Fastic, N-[(trans-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine, Starlix, Starsis

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C19H27NO3
Numéro CAS:
105816-04-4
Poids moléculaire :
317.42
Numéro MDL:
MFCD00875706
Code UNSPSC :
41116107
ID de substance PubChem :
329831425
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

nateglinide

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(O)=O

InChI

1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1

Clé InChI

OELFLUMRDSZNSF-BRWVUGGUSA-N

Informations sur le gène

human ... ABCC8(6833) , KCNJ11(3767)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nateglinide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Nateglinide, a new agent for postprandial glucose control in type 2 diabetes.
Srividya Kotapati
Connecticut medicine, 66(5), 269-272 (2002-06-20)
Nicholas Tentolouris et al.
Vascular health and risk management, 3(6), 797-807 (2008-01-19)
Impaired insulin secretion occurs early in the pathogenesis of type 2 diabetes mellitus (T2DM) and is chronic and progressive, resulting initially in impaired glucose tolerance (IGT) and eventually in T2DM. As most patients with T2DM have both insulin resistance and
[Nateglinide].
Yoko Notoya et al.
Nihon rinsho. Japanese journal of clinical medicine, 60 Suppl 9, 371-375 (2002-10-22)
C J Halas
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 58(13), 1200-1205 (2001-07-14)
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, interactions, and dosage of nateglinide are reviewed. Nateglinide is an oral hypoglycemic agent approved for use alone or in combination with metformin as an adjunct to diet and exercise for the treatment of
George Grunberger
Expert opinion on pharmacotherapy, 12(13), 2097-2106 (2011-08-02)
It has been hypothesized that reducing postprandial glucose spikes would result both in improved overall glycemic control and long-term (especially cardiovascular) outcomes in patients with type 2 diabetes. Nateglinide, a short-acting insulin secretagogue of the meglitinide class of antidiabetic agents
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique